Health economic and outcomes research datasets have rarely been integral to product development and communication plans.
FDA approves Merck's HCV doublet regimen; Gilead CEO steps down; Clinton takes aim at Valeant price hikes
Sanofi is the category leader. Its product, Lantus Solostar, brought in $5.27 billion in US sales between October 2014 and September 2015.
New entrants in the type 2 diabetes treatment market share a similar goal: To solve patients' constant struggle with glycemic control.
Experts insist that R&D efforts in the category must mirror educational campaigns and lifestyle changes, and quickly.
NICE recommends Opdivo for skin cancer; Sanofi layoffs could be looming; Senators ask for feedback on Sovaldi investigation
Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup
The FDA in November approved three new drugs that treat the rare blood cancer.
GSK will stop using outside doctors to promote its drugs; Roche will file its immuno-oncology drug for approval; Mylan inks deal to develop six biosimilars
Gilead's hep-C combo gets Breakthrough designation; Baxalta licences experimental cancer drugs; Novartis agrees to settle class-action lawsuit
With the huge advances in treatment comes a raft of concerns, among them daunting pricing pressures.
GlaxoSmithKline buys Bristol-Myers Squibb's research assets; Gilead Sciences makes large stake in experimental rheumatoid arthritis drug; Avandia's REMS program ends
Eli Lilly and Boehringer Ingelheim received approval to begin selling their Lantus knock-off drug after settling a patent lawsuit with Sanofi in September.
An FDA advisory committee voted 11-3, recommending approval of reslizumab in adults with severe asthma.
Gleevec generic is approved; FDA issues warning on diabetes drugs; Senate will hold hearing on drug pricing
GlaxoSmithKline announced that it signed a development agreement with Propeller Health to use its sensors in clinical trials.
Opdivo's new melanoma indication denied; Novartis weighs sale of contact lens portfolio; Sanofi prepares to sell Merial
A peek at 159 aspiring agents, with profiles on 17 that could shoot to stardom. Rebecca Mayer Knutsen has the forecast
Addyi off to a slow start; Dr. Robert Califf faces Senate committee on FDA nomination; FDA grants Opdivo Breakthrough Therapy Designation in kidney cancer
PBMs crack down on specialty pharmacies; Merck's cholesterol drug soldiers on; rare-disease drug nabs approval
Harvoni's label is expanded; AstraZeneca lung-cancer drug receives accelerated approval; Mylan's Perrigo takeover falls short
Not-for-profit ranks Gilead Sciences and Sanofi as the lowest-scoring drugmakers in terms of clinical trial transparency; Perrigo shareholders to vote on Mylan deal; new Valeant allegations
Executives at Eli Lilly, Merck and Biogen used the most recent earnings season to promote innovation and defend drug pricing.
GSK partners with other drugmakers to bolster pipeline; Pfizer makes deal in South Africa for Prevnar 13; the FDA issues guidance on HIV biologic development
Walgreens buys Rite Aid in $9.4 billion deal; Arena fires a third of its workforce and discontinues Belviq clinical trials; FDA approves Amgen melanoma immunotherapy
Oncologist perception of diagnostics may grow as immuno-oncology treatments move toward first-line use, drugmaker execs say.
FDA panel recommends AZ gout drug for approval; Valeant to form committee to examine specialty pharmacy ties; patients treated with Keytruda had longer survival than those who took chemo
Therapy and low-dose drugs found to aid schizophrenia patients more than just antipsychotics; Clinton calls for investigations into drug price increases; Bayer issues RFP for AOR for consumer care brands
The FDA approves Pradaxa antidote; Valeant CEO says he expects a new pricing environment in 2016; FDA denies Shire dry-eye drug
The NIH plans to fund fewer but more meaningful studies; the FDA asks for more data about AstraZeneca diabetes drug; payers continue to deny coverage for new hep.-C treatments